nidНефрология и диализNephrology and Dialysis1680-44222618-9801Российское диализное обществоnid-3770Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESУровни Ил-10, Ил-8 в крови детей с различными вариантами стероидчувствительного нефротического синдрома первичного хронического гломерулонефритаIL-10, IL-8 in Serum of Children with Different Variants of Steroid-Sensitive Nephrotic Syndrome of Primary Chronic GlomerulonephritisВашуринаТ. В.VashurinaT. V.noemail@neicon.ruСенцоваТ. Б.SentsovaT. B.noemail@neicon.ruСергееваТ. В.SergeevaT. V.noemail@neicon.ruНаучный центр здоровья детей РАМН, МоскваRussian Federation20002806202523163165Copyright © Вашурина Т.В., Сенцова Т.Б., Сергеева Т.В., 20252025Вашурина Т.В., Сенцова Т.Б., Сергеева Т.В.Vashurina T.V., Sentsova T.B., Sergeeva T.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephro.ru/jour/article/view/3770

Экспериментальные данные, касающиеся исследований нарушенной цитокиновой продукции при нефротическом синдроме с минимальными изменениями (НСМИ), весьма противоречивы. Недостаток интерлейкина-10 (Ил-10), подавляющего секрецию васкулярного фактора проницаемости и многих провоспалительных цитокинов, играет важную роль в развитии этого состояния. Тем не менее, факты о дисбалансе его продукции в клинических условиях особенно малочисленны. Нами проведены непосредственное измерение и анализ Ил-10 и Ил-8 в крови 7 детей со стероидчувствительным нефротическим синдромом. У больного в активной стадии заболевания уровень Ил-10 был снижен до 0,8 пг/мл с последующим увеличением в начале ремиссии до 5 пг/мл (в 6 раз). В стадии ремиссии стероидзависимого НС Ил-8 не обнаружен ни у одного пациента, Ил-10 в крови четверых больных был повышен по сравнению с его уровнем у здоровых детей. Таким образом, повышенная продукция Ил-10 в начале ремиссии с последующей ее нормализацией способствует устранению дисфункции Т-лимфоцитов, ингибиции Ил-8 и переходу активной стадии в ремиссию стероидчувствительного НС.

Experimental data concerning cytokine production dysfunction associated with nephrotic syndrome with minimal change are highly controversial. The insufficiency of interleikyne-10 (IL-10) which suppresses vascular permeability factor and many other anti-inflammatory cytokines secretion play an important role in the development of this condition. Data on disbalanced production of IL-10 in clinic are particularly insufficient. We conducted the direct measurements and analyzed IL-10 and IL-8 blood level in 7 children with steroid-sensitive nephrotic syndrome. The patient in the acute phase of the disease had the decreased down to 0.8 pg/ml IL-10 level. It increased up to 5 pg/ml (6 times) at the beginning of remission. IL-8 was not found in any patient with the remission period of steroid-sensitive nephrotic syndrome, IL-10 in 4 patients was higher normal. Thus the increased IL-10 production at the beginning of remission with its consequent normalization contributes to the elimination of T-lymphocytes dysfunction, IL-8 inhibition and promotes the active phase- remission period transition of the steroid-sensitive nephrotic syndrome.

интерлейкин-10интерлейкин-8стероидчувствительный нефротический синдромReferencesDaniel V., Trautmann Y., Konrad M. et al. T-lymphocyte populations, cytokines and other growth factors in serum and urine of children with idiopathic nephrotic syndrome. Clin Nephrol 1997; 47: 289-297.Daniel V., Trautmann Y., Konrad M. et al. T-lymphocyte populations, cytokines and other growth factors in serum and urine of children with idiopathic nephrotic syndrome. Clin Nephrol 1997; 47: 289-297.Fiser R.T., Arnold W.C., Charlton R.K. et al. T-lymphocute subsets in nephrotic syndrome. Kid Int 1991; 40: 913-916.Fiser R.T., Arnold W.C., Charlton R.K. et al. T-lymphocute subsets in nephrotic syndrome. Kid Int 1991; 40: 913-916.Garin E.H., Blanchard D.K., Matsushima K., Djeu J.Y. IL-8 production by peripheral blood mononuclear cells in nephrotic patients. Kid Int 1994; 45: 1311-1317.Garin E.H., Blanchard D.K., Matsushima K., Djeu J.Y. IL-8 production by peripheral blood mononuclear cells in nephrotic patients. Kid Int 1994; 45: 1311-1317.Hulton S.A., Shah V., Byrne M.R. et al. Lymphocyte subpopulations, interleukin-2 and interleukin-2 receptor expression in childhood nephrotic syndrome. Pedietr Nephrol 1994; 8: 135-139.Hulton S.A., Shah V., Byrne M.R. et al. Lymphocyte subpopulations, interleukin-2 and interleukin-2 receptor expression in childhood nephrotic syndrome. Pedietr Nephrol 1994; 8: 135-139.Kobayashi K., Yoshikawa N., Nakamura H. T-cell subpopulation in childhood nephrotic syndrome. Clin Nephrol 1994; 41: 253-258.Kobayashi K., Yoshikawa N., Nakamura H. T-cell subpopulation in childhood nephrotic syndrome. Clin Nephrol 1994; 41: 253-258.Matsumoto K., Osakabe K., Katayama H., Hatano M. In vitro lymphocyte disfunction in lipoid nephrosis mediated by suppressor cells. Nephron 1982; 32: 270-272.Matsumoto K., Osakabe K., Katayama H., Hatano M. In vitro lymphocyte disfunction in lipoid nephrosis mediated by suppressor cells. Nephron 1982; 32: 270-272.Matsumoto K. Interleukin 10 inhibits vascular permeability factor release by peripheral blood mononuclear cells in patients with lipoid nephrosis. Nephron 1997; 75: 154-159.Matsumoto K. Interleukin 10 inhibits vascular permeability factor release by peripheral blood mononuclear cells in patients with lipoid nephrosis. Nephron 1997; 75: 154-159.Matsumoto K., Ohi H., Kanmatsuse K. Interleukin 10 and interleukin 13 synergize to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with lipoid nephrosis. Nephron 1997; 77: 212-218.Matsumoto K., Ohi H., Kanmatsuse K. Interleukin 10 and interleukin 13 synergize to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with lipoid nephrosis. Nephron 1997; 77: 212-218.Matsumoto K., Ohi H., Kanmatsuse K. Interleukin-4 cooperates with interleukin-10 to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with minimal change nephrotic syndrome. Am J Nephrol 1999; 19: 21-27.Matsumoto K., Ohi H., Kanmatsuse K. Interleukin-4 cooperates with interleukin-10 to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with minimal change nephrotic syndrome. Am J Nephrol 1999; 19: 21-27.Matsumoto K. Decreased release of IL-10 by monocytes from patients with lipoid nephrosis. Clin Exp Immunol 1995; 102: 603-607.Matsumoto K. Decreased release of IL-10 by monocytes from patients with lipoid nephrosis. Clin Exp Immunol 1995; 102: 603-607.Neuhaus T.J., Wadhwa M., Callard R., Barratt T.M. Increased IL-2, IL-4 and interferon-gamma (IFN-г) in steroid-sensitive nephrotic syndrome. Clin Exp Immunol 1995; 100: 475-479.Neuhaus T.J., Wadhwa M., Callard R., Barratt T.M. Increased IL-2, IL-4 and interferon-gamma (IFN-г) in steroid-sensitive nephrotic syndrome. Clin Exp Immunol 1995; 100: 475-479.Neuhaus T.J., Shah V., Callard R., Barratt T.M. T-lymphocyte activation in steroid-sensitive nephrotic syndrome in childhood. Nephrol Dial Transplant 1995; 10: 1348-1352.Neuhaus T.J., Shah V., Callard R., Barratt T.M. T-lymphocyte activation in steroid-sensitive nephrotic syndrome in childhood. Nephrol Dial Transplant 1995; 10: 1348-1352.Schnaper H.W. The immune system in minimal change nephrotic syndrome. Pediatr Nephrol 1989; 3: 101-110.Schnaper H.W. The immune system in minimal change nephrotic syndrome. Pediatr Nephrol 1989; 3: 101-110.Webb N.J.A., Postlethwaite R.J., Lewis M.A., Brenchlay P.E.C. Increased expression of vascular permeability factor (VPF) during relapse of childhood steroid sensitive nephrotic syndrome (SSNS). J Am Soc Nephrol 1994; 5: 845.Webb N.J.A., Postlethwaite R.J., Lewis M.A., Brenchlay P.E.C. Increased expression of vascular permeability factor (VPF) during relapse of childhood steroid sensitive nephrotic syndrome (SSNS). J Am Soc Nephrol 1994; 5: 845.Yoshisawa N., Kusumi Y., Matsumoto K. et al. Studies of a glomerular permeability factor in patients with minimal change nephrotic syndrome. Nephron 1989; 51: 370-376.Yoshisawa N., Kusumi Y., Matsumoto K. et al. Studies of a glomerular permeability factor in patients with minimal change nephrotic syndrome. Nephron 1989; 51: 370-376.

The authors declare that there are no conflicts of interest present.